Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072199 | 0.82 | MCL1 (0.62) | L3MBTL1MCL1TSHRPPARGPPARD | |
| SCHEMBL4072882 | 0.81 | TSHR (0.59) | L3MBTL1TSHRHTT | |
| SCHEMBL3723832 | 0.79 | L3MBTL1 (0.66) | L3MBTL1MCL1TSHRPPARGPPARD | |
| SCHEMBL11586955 | 0.75 | MCL1 (0.71) | L3MBTL1MCL1FFAR4 | |
| SCHEMBL2775814 | 0.74 | L3MBTL1 (0.58) | L3MBTL1MCL1TSHRPPARGPPARD | |
| SCHEMBL1806524 | 0.73 | L3MBTL1 (1.00) | L3MBTL1MCL1TSHRMMP2FFAR4 | |
| SCHEMBL3172535 | 0.72 | L3MBTL1 (0.57) | L3MBTL1MCL1TSHRPPARGPPARD | |
| SCHEMBL19433595 | 0.72 | MCL1 (0.64) | L3MBTL1MCL1TSHRPPARGMMP2 | |
| SCHEMBL3177267 | 0.71 | TSHR (0.61) | L3MBTL1MCL1TSHRPPARGPPARD | |
| SCHEMBL2777259 | 0.71 | L3MBTL1 (0.64) | L3MBTL1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547933-A | Radiofluorination | BAYER SCHERING PHARMA AG (DE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035215-A1 | RADIOFLUORINATION | AFF2, AFF1, NUTF2 | L3MBTL1 299/4885MCL1 2218/4885TSHR 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.